COMPASS Pathways (NASDAQ:CMPS – Free Report) had its price target reduced by HC Wainwright from $60.00 to $45.00 in a report ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, a ...

H.C. Wainwright analyst Patrick Trucchio revised the price target on Compass Pathways (NASDAQ:CMPS) stock, reducing it to $45 ...

H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $45 from $60 and keeps a Buy rating on the shares. The firm says ...

Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) have received a consensus recommendation of “Buy” from the six ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of ...

Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.